Table 4. CIHR panels exhibiting a significant tendency to not award grants re: sex and/or gender.
| Panel | Pertinent to Sex | Pertinent to Gender |
| Biochemistry & Molecular Biology - A (BMA) | 0 of 26 | 0 of 26 |
| Cell Biology & Mechanisms of Disease (CBM) | 3 of 34 | 0 of 34 |
| Cell Physiology (CP) | 0 of 27 | 0 of 27 |
| Cancer Progression & Therapeutics (CPT a.k.a. CT2) | 6 of 56 | 3 of 56 |
| Developmental Biology (DEV) | 1 of 22 | 0 of 22 |
| Immunology & Transplantation (IT) | 4 of 37 | 0 of 37 |
| Systems & Clinical Neurosciences (NSA) | 5 of 39 | 1 of 39 |
| Molecular & Cellular Neurosciences (NSB) | 3 of 31 | 1 of 31 |
| Behavioural Sciences - B (BSB) (Clinical Behavioural Sciences) | 1 of 18 | 1 of 18 |
| Cancer Biology & Therapeutics (CBT) | 2 of 30 | 2 of 30 |
| Molecular & Cellular Biology of Cancer (MCC) | 3 of 29 | 1 of 29 |
| Microbiology & Infectious Diseases (MID) | 3 of 30 | 3 of 30 |
| Behavioural Sciences - A (BSA) (Behavioural Studies in Animal Models) | 6 of 30 | 0 of 22 |
| Clinical Investigation - B (CIB) (Arthritis, Bone, Skin and Cartilage) | 12 of 49 | 2 of 49 |
| Cardiovascular System - A (CSA) (Cells & Tissues) | 4 of 21 | 0 of 21 |
| Cardiovascular System - B (CSB) (Basic translational research in Cardiovascular Sciences) | 8 of 27 | 0 of 27 |
| Pharmaceutical Sciences (PS) | 6 of 38 | 0 of 38 |
(Italicized items have a P-Value above 0.05/no significant tendency).